A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life. This makes individuals more susceptible to viral diseases like COVID ...
CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced ...
A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life. This makes individuals more susceptible to viral diseases like COVID ...
Investigators studied expression of type I interferons, key pathogenic drivers in systemic lupus erythematosus and lupus nephritis.
Auto-antibodies erroneously target their own proteins and enzymes. When these auto-antibodies target type 1 interferons, they can neutralize their function as signal proteins for the immune system.
Type 1 interferons (IFNs) play a central role in the development and disease course of systemic lupus erythematosus (SLE). In a new study, researchers explored SLE disease activity and type I ...
LONDON, United Kingdom — After years of clinical trial failures, an anti-interferon antibody, anifrolumab, has been shown to dramatically reduce disease activity in extrarenal systemic lupus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results